A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

Détails

Ressource 1Télécharger: 38584069.pdf (2487.05 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_7A92BC1E6EB4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Périodique
Clinical lung cancer
Auteur⸱e⸱s
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S.W., Ursol G., Hussein M., Lim F.L., Yang C.T., Araujo L.H., Saito H., Reinmuth N., Kohlmann M., Lowery C., Mann H., Peters S., Mok T.S., Johnson M.L.
ISSN
1938-0690 (Electronic)
ISSN-L
1525-7304
Statut éditorial
Publié
Date de publication
05/2024
Peer-reviewed
Oui
Volume
25
Numéro
3
Pages
266-273.e5
Langue
anglais
Notes
Publication types: Journal Article ; Clinical Trial, Phase III
Publication Status: ppublish
Mots-clé
Humans, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal/therapeutic use, B7-H1 Antigen/metabolism, B7-H1 Antigen/antagonists & inhibitors, Male, Female, Treatment Outcome, Clinical trial, Cytotoxic T-lymphocyte-associated antigen 4, Immune checkpoint inhibitor, Immunotherapy, Programmed cell death ligand-1
Pubmed
Open Access
Oui
Création de la notice
12/04/2024 9:16
Dernière modification de la notice
22/05/2024 7:13
Données d'usage